Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in:

Open Access 01-12-2024 | Review

Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope

Authors: Xiaojie Zhang, Bufu Tang, Jinhua Luo, Yang Yang, Qiaoyou Weng, Shiji Fang, Zhongwei Zhao, Jianfei Tu, Minjiang Chen, Jiansong Ji

Published in: Molecular Cancer | Issue 1/2024

Login to get access

Abstract

Normal life requires cell division to produce new cells, but cell death is necessary to maintain balance. Dysregulation of cell death can lead to the survival and proliferation of abnormal cells, promoting tumor development. Unlike apoptosis, necrosis, and autophagy, the newly recognized forms of regulated cell death (RCD) cuproptosis, ferroptosis, and PANoptosis provide novel therapeutic strategies for tumor treatment. Increasing research indicates that the death of tumor and immune cells mediated by these newly discovered forms of cell death can regulate the tumor microenvironment (TME) and influence the effectiveness of tumor immunotherapy. This review primarily elucidates the molecular mechanisms of cuproptosis, ferroptosis, and PANoptosis and their complex effects on tumor cells and the TME. This review also summarizes the exploration of nanoparticle applications in tumor therapy based on in vivo and in vitro evidence derived from the induction or inhibition of these new RCD pathways.
Literature
1.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.PubMedPubMedCentralCrossRef
2.
Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7(1):286.PubMedPubMedCentralCrossRef
3.
Hu J, Zhang R, Chang Q, Ji M, Zhang H, Geng R, et al. p53: a Regulator of Ferroptosis Induced by Galectin-1 derived peptide 3 in MH7A cells. Front Genet. 2022;13:920273.PubMedPubMedCentralCrossRef
4.
5.
Proskuryakov SY, Gabai VL. Mechanisms of tumor cell necrosis. Curr Pharm Design. 2010;16(1):56–68.CrossRef
6.
Morana O, Wood W, Gregory CD. The apoptosis Paradox in Cancer. Int J Mol Sci. 2022;23(3).
7.
8.
9.
10.
Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. From nature to bedside: pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Biotechnol Adv. 2014;32(6):1111–22.PubMedCrossRef
11.
Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X, et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res. 2023;42(1):142.PubMedPubMedCentralCrossRef
12.
13.
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Sci (New York NY). 2022;375(6586):1254–61.CrossRef
14.
Roberts EA, Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper. Am J Clin Nutr. 2008;88(3):s851–4.CrossRef
15.
16.
Wang Y, Hodgkinson V, Zhu S, Weisman GA, Petris MJ. Advances in the understanding of mammalian copper transporters. Advances in nutrition (Bethesda. Md). 2011;2(2):129–37.
17.
18.
Narindrasorasak S, Zhang X, Roberts EA, Sarkar B. Comparative analysis of metal binding characteristics of copper chaperone proteins, Atx1 and ATOX1. Bioinorg Chem Appl. 2004;2(1–2):105–23.PubMedPubMedCentralCrossRef
19.
Duan WJ, He RR. Cuproptosis: copper-induced regulated cell death. Sci China Life Sci. 2022;65(8):1680–2.PubMedCrossRef
20.
Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15(7):681–9.PubMedPubMedCentralCrossRef
21.
Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008;7(8):2319–27.PubMedCrossRef
22.
Babak MV, Ahn D. Modulation of intracellular copper levels as the mechanism of action of Anticancer Copper complexes: clinical relevance. Biomedicines. 2021;9(8).
23.
Zhao G, Sun H, Zhang T, Liu JX. Copper induce zebrafish retinal developmental defects via triggering stresses and apoptosis. Cell Communication Signaling: CCS. 2020;18(1):45.PubMedPubMedCentralCrossRef
24.
Huo S, Wang Q, Shi W, Peng L, Jiang Y, Zhu M et al. ATF3/SPI1/SLC31A1 signaling promotes Cuproptosis Induced by Advanced Glycosylation End products in Diabetic Myocardial Injury. Int J Mol Sci. 2023;24(2).
25.
Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartnikas TB, Culotta VC, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA. 2000;97(6):2886–91.PubMedPubMedCentralCrossRef
26.
Aich A, Wang C, Chowdhury A, Ronsör C, Pacheu-Grau D, Richter-Dennerlein R et al. COX16 promotes COX2 metallation and assembly during respiratory complex IV biogenesis. eLife. 2018;7.
27.
Pacheu-Grau D, Bareth B, Dudek J, Juris L, Vögtle FN, Wissel M, et al. Cooperation between COA6 and SCO2 in COX2 maturation during cytochrome c oxidase assembly links two mitochondrial cardiomyopathies. Cell Metabol. 2015;21(6):823–33.CrossRef
28.
Scheiber I, Dringen R, Mercer JF. Copper: effects of deficiency and overload. Metal Ions Life Sci. 2013;13:359–87.CrossRef
29.
Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102–13.PubMedCrossRef
30.
Shanbhag VC, Gudekar N, Jasmer K, Papageorgiou C, Singh K, Petris MJ. Copper metabolism as a unique vulnerability in cancer. Biochim Biophys Acta Mol Cell Res. 2021;1868(2):118893.PubMedCrossRef
31.
32.
Santoro AM, Monaco I, Attanasio F, Lanza V, Pappalardo G, Tomasello MF, et al. Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study. Sci Rep. 2016;6:33444.PubMedPubMedCentralCrossRef
33.
Xiao Y, Chen DI, Zhang X, Cui Q, Fan Y, Bi C, et al. Molecular study on copper-mediated tumor proteasome inhibition and cell death. Int J Oncol. 2010;37(1):81–7.PubMed
34.
Tsang T, Posimo JM, Gudiel AA, Cicchini M, Feldser DM, Brady DC. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol. 2020;22(4):412–24.PubMedPubMedCentralCrossRef
35.
Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011;71(5):1561–72.PubMedCrossRef
36.
Shanbhag V, Jasmer-McDonald K, Zhu S, Martin AL, Gudekar N, Khan A, et al. ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis. Proc Natl Acad Sci USA. 2019;116(14):6836–41.PubMedPubMedCentralCrossRef
37.
Chen X, Clement M, Hicks MJ, Sarkar P, Gaber MW, Man TK. LOX upregulates FAK phosphorylation to promote metastasis in osteosarcoma. Genes Dis. 2023;10(1):254–66.PubMedCrossRef
38.
Voli F, Valli E, Lerra L, Kimpton K, Saletta F, Giorgi FM, et al. Intratumoral Copper modulates PD-L1 expression and influences Tumor Immune Evasion. Cancer Res. 2020;80(19):4129–44.PubMedCrossRef
39.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.PubMedPubMedCentralCrossRef
40.
Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, et al. Neuronal death after hemorrhagic stroke in Vitro and in vivo shares features of ferroptosis and Necroptosis. Stroke. 2017;48(4):1033–43.PubMedPubMedCentralCrossRef
41.
Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12(8):1425–8.
42.
43.
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Reviews Clin Oncol. 2021;18(5):280–96.CrossRef
44.
Imoto S, Kono M, Suzuki T, Shibuya Y, Sawamura T, Mizokoshi Y, et al. Haemin-induced cell death in human monocytic cells is consistent with ferroptosis. Transfus Apheresis Science: Official J World Apheresis Association : Official J Eur Soc Haemapheresis. 2018;57(4):524–31.
45.
Do Van B, Gouel F, Jonneaux A, Timmerman K, Gelé P, Pétrault M, et al. Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis. 2016;94:169–78.PubMedCrossRef
46.
47.
48.
49.
Rink JS, Lin AY, McMahon KM, Calvert AE, Yang S, Taxter T, et al. Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. J Biol Chem. 2021;296:100100.PubMedCrossRef
50.
51.
Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.PubMedPubMedCentralCrossRef
52.
Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–91.PubMedPubMedCentralCrossRef
53.
Wang Y, Yang L, Zhang X, Cui W, Liu Y, Sun QR, et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 2019;20(7):e47563.PubMedPubMedCentralCrossRef
54.
Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017;20(7):1692–704.PubMedCrossRef
55.
Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 suppresses metabolic stress-Induced ferroptosis in Cancer cells. Cell Rep. 2018;22(3):569–75.PubMedPubMedCentralCrossRef
56.
Ou Y, Wang SJ, Li D, Chu B, Gu W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci USA. 2016;113(44):E6806–12.PubMedPubMedCentralCrossRef
57.
Leu JI, Murphy ME, George DL. Mechanistic basis for impaired ferroptosis in cells expressing the african-centric S47 variant of p53. Proc Natl Acad Sci USA. 2019;116(17):8390–6.PubMedPubMedCentralCrossRef
58.
Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149(6):1269–83.PubMedPubMedCentralCrossRef
59.
Kon N, Ou Y, Wang SJ, Li H, Rustgi AK, Gu W. mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression. Genes Dev. 2021;35(1–2):59–64.PubMedPubMedCentralCrossRef
60.
Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572(7769):402–6.PubMedPubMedCentralCrossRef
61.
Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D, et al. The Hippo Pathway Effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep. 2019;28(10):2501–e84.PubMedPubMedCentralCrossRef
62.
Zheng Y, Li J, Liu B, Xie Z, He Y, Xue D, et al. Global trends in PANoptosis research: bibliometrics and knowledge graph analysis. Apoptosis: Int J Program cell Death. 2024;29(1–2):229–42.CrossRef
63.
Karki R, Lee S, Mall R, Pandian N, Wang Y, Sharma BR, et al. ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Sci Immunol. 2022;7(74):eabo6294.PubMedCrossRef
64.
Lee S, Karki R, Wang Y, Nguyen LN, Kalathur RC, Kanneganti TD. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597(7876):415–9.PubMedPubMedCentralCrossRef
65.
Malireddi RKS, Kesavardhana S, Karki R, Kancharana B, Burton AR, Kanneganti TD. RIPK1 distinctly regulates Yersinia-Induced Inflammatory Cell Death, PANoptosis. ImmunoHorizons. 2020;4(12):789–96.PubMedCrossRef
66.
Kuriakose T, Man SM, Malireddi RK, Karki R, Kesavardhana S, Place DE et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci Immunol. 2016;1(2).
67.
68.
Mall R, Bynigeri RR, Karki R, Malireddi RKS, Sharma BR, Kanneganti TD. Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology. NAR cancer. 2022;4(4):zcac033.PubMedPubMedCentralCrossRef
69.
Karki R, Sundaram B, Sharma BR, Lee S, Malireddi RKS, Nguyen LN, et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell Rep. 2021;37(3):109858.PubMedPubMedCentralCrossRef
70.
Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and Mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184(1):149–e6817.PubMedCrossRef
71.
Pandian N, Kanneganti TD. PANoptosis: a unique Innate Immune Inflammatory Cell Death Modality. J Immunol (Baltimore Md: 1950). 2022;209(9):1625–33.CrossRef
72.
73.
Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535(7610):153–8.PubMedPubMedCentralCrossRef
74.
Li W, Shen MM. Prostate cancer cell heterogeneity and plasticity: insights from studies of genetically-engineered mouse models. Sem Cancer Biol. 2022;82:60–7.CrossRef
75.
76.
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Reviews Clin Oncol. 2020;17(7):395–417.CrossRef
77.
78.
Guo Y, Tan J, Miao Y, Sun Z, Zhang Q. Effects of Microvesicles on cell apoptosis under Hypoxia. Oxidative Med Cell Longev. 2019;2019:5972152.CrossRef
79.
O’Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev. 2016;30(8):973–88.PubMedPubMedCentralCrossRef
80.
Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.PubMedCrossRef
81.
Flores-Romero H, Hohorst L, John M, Albert MC, King LE, Beckmann L, et al. BCL-2-family protein tBID can act as a BAX-like effector of apoptosis. EMBO J. 2022;41(2):e108690.PubMedCrossRef
82.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479–89.PubMedCrossRef
83.
Hu Q, Wu D, Chen W, Yan Z, Yan C, He T, et al. Molecular determinants of caspase-9 activation by the Apaf-1 apoptosome. Proc Natl Acad Sci USA. 2014;111(46):16254–61.PubMedPubMedCentralCrossRef
84.
Zhou M, Li Y, Hu Q, Bai XC, Huang W, Yan C, et al. Atomic structure of the apoptosome: mechanism of cytochrome c- and dATP-mediated activation of Apaf-1. Genes Dev. 2015;29(22):2349–61.PubMedPubMedCentralCrossRef
85.
86.
Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell. 2000;103(6):839–42.PubMedCrossRef
87.
Gao J, Xiong A, Liu J, Li X, Wang J, Zhang L et al. PANoptosis: bridging apoptosis, pyroptosis, and necroptosis in cancer progression and treatment. Cancer Gene Ther. 2024.
88.
Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N, et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods (San Diego Calif). 2013;61(2):117–29.PubMedCrossRef
89.
Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21(11):678–95.PubMedCrossRef
90.
Seo J, Nam YW, Kim S, Oh DB, Song J. Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators. Exp Mol Med. 2021;53(6):1007–17.PubMedPubMedCentralCrossRef
91.
Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: mechanisms and relevance to Disease. Annu Rev Pathol. 2017;12:103–30.PubMedCrossRef
92.
93.
94.
Blaser H, Dostert C, Mak TW, Brenner D. TNF and ROS crosstalk in inflammation. Trends Cell Biol. 2016;26(4):249–61.PubMedCrossRef
95.
Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517(7534):311–20.PubMedCrossRef
96.
97.
98.
Banoth B, Tuladhar S, Karki R, Sharma BR, Briard B, Kesavardhana S, et al. ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). J Biol Chem. 2020;295(52):18276–83.PubMedCrossRef
99.
Malireddi RKS, Kesavardhana S, Kanneganti TD. ZBP1 and TAK1: Master regulators of NLRP3 Inflammasome/Pyroptosis, apoptosis, and necroptosis (PAN-optosis). Front Cell Infect Microbiol. 2019;9:406.PubMedPubMedCentralCrossRef
100.
Yan WT, Yang YD, Hu XM, Ning WY, Liao LS, Lu S, et al. Do pyroptosis, apoptosis, and necroptosis (PANoptosis) exist in cerebral ischemia? Evidence from cell and rodent studies. Neural Regeneration Res. 2022;17(8):1761–8.CrossRef
101.
Wang Y, Pandian N, Han JH, Sundaram B, Lee S, Karki R, et al. Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method. Cell Mol Life Sci. 2022;79(10):531.PubMedCrossRef
102.
Samir P, Malireddi RKS, Kanneganti TD. The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020;10:238.PubMedPubMedCentralCrossRef
103.
Christgen S, Zheng M, Kesavardhana S, Karki R, Malireddi RKS, Banoth B, et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020;10:237.PubMedPubMedCentralCrossRef
104.
Sundaram B, Pandian N, Mall R, Wang Y, Sarkar R, Kim HJ, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023;186(13):2783–e80120.PubMedPubMedCentralCrossRef
105.
Zhu P, Ke ZR, Chen JX, Li SJ, Ma TL, Fan XL. Advances in mechanism and regulation of PANoptosis: prospects in disease treatment. Front Immunol. 2023;14:1120034.PubMedPubMedCentralCrossRef
106.
Liu Z, Sun L, Peng X, Zhu J, Wu C, Zhu W, et al. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer. Apoptosis: Int J Program cell Death. 2024;29(5–6):799–815.CrossRef
107.
Zhong L, Qian W, Gong W, Zhu L, Wang X. Molecular subtypes based on PANoptosis genes and characteristics of Immune Infiltration in Cutaneous Melanoma. Cellular and molecular biology. France). 2023;69(8):1–8. (Noisy-le-Grand.
108.
Karki R, Sharma BR, Lee E, Banoth B, Malireddi RKS, Samir P et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI Insight. 2020;5(12).
109.
Lou Y, Chen D, Gu Q, Zhu Q, Sun H. PANoptosis-related molecule CASP2 affects the immune microenvironment and immunotherapy response of hepatocellular carcinoma. Heliyon. 2024;10(6):e27302.PubMedPubMedCentralCrossRef
110.
Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther. 2002;1(1):65–9.PubMedCrossRef
111.
112.
Heidaryan F, Bamehr H, Babaabasi B, Emamvirdizadeh A, Mohammadzadeh N, Khalili A. The Trend of ripk1/ripk3 and mlkl mediated necroptosis pathway in patients with different stages of prostate Cancer as promising progression biomarkers. Clin Lab. 2020;66(3).
113.
Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, et al. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. J Translational Med. 2022;20(1):444.CrossRef
114.
Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15(11):669–82.PubMedCrossRef
115.
Koliaraki V, Pallangyo CK, Greten FR, Kollias G. Mesenchymal cells in Colon cancer. Gastroenterology. 2017;152(5):964–79.PubMedCrossRef
116.
López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32(2):135–54.PubMedCrossRef
117.
Garber K. Cancer’s copper connections. Sci (New York NY). 2015;349(6244):129.CrossRef
118.
De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep. 2019;9(1):11472.PubMedPubMedCentralCrossRef
119.
120.
Cheng F, Peng G, Lu Y, Wang K, Ju Q, Ju Y, et al. Relationship between copper and immunity: the potential role of copper in tumor immunity. Front Oncol. 2022;12:1019153.PubMedPubMedCentralCrossRef
121.
Xu S, Dong K, Gao R, Yang Y, Zhou Y, Luo C, et al. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(13):12249–63.PubMedCrossRef
122.
Tian X, Zhu S, Liu W, Wu X, Wei G, Zhang J, et al. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2023;149(19):17451–66.PubMedCrossRef
123.
Huang Y, Gong P, Su L, Zhang M. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma. Sci Rep. 2023;13(1):20870.PubMedPubMedCentralCrossRef
124.
Mi J, Luo J, Zeng H, Zhang H, Jamil M, Abdel-Maksoud MA, et al. Elucidating cuproptosis-related gene SLC31A1 diagnostic and prognostic values in cancer. Am J Translational Res. 2023;15(10):6026–41.
125.
Wang J, Li S, Guo Y, Zhao C, Chen Y, Ning W, et al. Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma. Funct Integr Genom. 2023;23(3):279.CrossRef
126.
Gángó A, Bátai B, Varga M, Kapczár D, Papp G, Marschalkó M, et al. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Virchows Archiv: Int J Pathol. 2018;473(4):453–62.CrossRef
127.
Zhu YD, Lu MY. Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis. Mol Med Rep. 2018;18(3):3403–10.PubMed
128.
Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-related risk score predicts prognosis and characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol. 2022;13:925618.PubMedPubMedCentralCrossRef
129.
Li H, Zu X, Hu J, Xiao Z, Cai Z, Gao N, et al. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma. Front Immunol. 2022;13:964393.PubMedPubMedCentralCrossRef
130.
Wu JH, Cheng TC, Zhu B, Gao HY, Zheng L, Chen WX. Identification of cuproptosis-related gene SLC31A1 and upstream LncRNA-miRNA regulatory axis in breast cancer. Sci Rep. 2023;13(1):18390.PubMedPubMedCentralCrossRef
131.
Ran XM, Xiao H, Tang YX, Jin X, Tang X, Zhang J, et al. The effect of cuproptosis-relevant genes on the immune infiltration and metabolism of gynecological oncology by multiply analysis and experiments validation. Sci Rep. 2023;13(1):19474.PubMedPubMedCentralCrossRef
132.
Quan Y, Li W, Yan R, Cheng J, Xu H, Chen L. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1. Front Oncol. 2023;13:1168769.PubMedPubMedCentralCrossRef
133.
Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365–e786.PubMedPubMedCentralCrossRef
134.
Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4.PubMedPubMedCentralCrossRef
135.
Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated Chemoresistance in Ovarian Cancer. Cell. 2016;165(5):1092–105.PubMedPubMedCentralCrossRef
136.
Yu B, Choi B, Li W, Kim DH. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat Commun. 2020;11(1):3637.PubMedPubMedCentralCrossRef
137.
Li K, Xu K, He Y, Yang Y, Tan M, Mao Y, et al. Oxygen Self-Generating Nanoreactor mediated ferroptosis activation and immunotherapy in Triple-negative breast Cancer. ACS Nano. 2023;17(5):4667–87.PubMedCrossRef
138.
Xie L, Li J, Wang G, Sang W, Xu M, Li W, et al. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy. J Am Chem Soc. 2022;144(2):787–97.PubMedCrossRef
139.
Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med. 2015;212(4):555–68.PubMedPubMedCentralCrossRef
140.
Drijvers JM, Gillis JE, Muijlwijk T, Nguyen TH, Gaudiano EF, Harris IS, et al. Pharmacologic screening identifies metabolic vulnerabilities of CD8(+) T cells. Cancer Immunol Res. 2021;9(2):184–99.PubMedCrossRef
141.
Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W et al. Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1/L1 Response. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2023;10(2):e2203973.
142.
Zhang B, Tang B, Lv J, Gao J, Qin L. Systematic analyses to explore immune gene sets-based signature in hepatocellular carcinoma, in which IGF2BP3 contributes to tumor progression. Clin Immunol (Orlando Fla). 2022;241:109073.CrossRef
143.
Tang B, Zhu J, Fang S, Wang Y, Vinothkumar R, Li M, et al. Pharmacological inhibition of MELK restricts ferroptosis and the inflammatory response in colitis and colitis-propelled carcinogenesis. Free Radic Biol Med. 2021;172:312–29.PubMedCrossRef
144.
Tang B, Zhu J, Li J, Fan K, Gao Y, Cheng S, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Communication Signaling: CCS. 2020;18(1):174.PubMedPubMedCentralCrossRef
145.
Wang Y, Tang B, Zhu J, Yu J, Hui J, Xia S, et al. Emerging mechanisms and targeted therapy of ferroptosis in neurological diseases and Neuro-Oncology. Int J Biol Sci. 2022;18(10):4260–74.PubMedPubMedCentralCrossRef
146.
Kapralov AA, Yang Q, Dar HH, Tyurina YY, Anthonymuthu TS, Kim R, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol. 2020;16(3):278–90.PubMedPubMedCentralCrossRef
147.
Luo X, Gong HB, Gao HY, Wu YP, Sun WY, Li ZQ, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28(6):1971–89.PubMedPubMedCentralCrossRef
148.
Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, De Pizzol M, et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010;40(3):824–35.PubMedCrossRef
149.
Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Investig. 2021;131(8).
150.
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore MD). 2016;63(1):173–84.PubMedCrossRef
151.
Poznanski SM, Singh K, Ritchie TM, Aguiar JA, Fan IY, Portillo AL, et al. Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. Cell Metabol. 2021;33(6):1205–e205.CrossRef
152.
Alsalman A, Al-Mterin MA, Murshed K, Alloush F, Al-Shouli ST, Toor SM et al. Circulating and Tumor-infiltrating Immune checkpoint-expressing CD8(+) Treg/T cell subsets and their associations with Disease-Free Survival in Colorectal Cancer patients. Cancers (Basel). 2022;14(13).
153.
Xu C, Sun S, Johnson T, Qi R, Zhang S, Zhang J, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35(11):109235.PubMedCrossRef
154.
Datta S, Kundu S, Ghosh P, De S, Ghosh A, Chatterjee M. Correlation of oxidant status with oxidative tissue damage in patients with rheumatoid arthritis. Clin Rheumatol. 2014;33(11):1557–64.PubMedCrossRef
155.
Wu J, Feng Z, Chen L, Li Y, Bian H, Geng J, et al. TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models. Nat Commun. 2022;13(1):676.PubMedPubMedCentralCrossRef
156.
Marmonti E, Oliva-Ramirez J, Haymaker C. Dendritic cells: the Long and Evolving Road towards successful targetability in Cancer. Cells. 2022;11:19.CrossRef
157.
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527–38.PubMedPubMedCentralCrossRef
158.
Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8(2).
159.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1).
160.
Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11(1):5424.PubMedPubMedCentralCrossRef
161.
162.
Ketelut-Carneiro N, Fitzgerald KA. Apoptosis, pyroptosis, and Necroptosis-Oh my! The many ways a cell can die. J Mol Biol. 2022;434(4):167378.PubMedCrossRef
163.
White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell. 2014;159(7):1549–62.PubMedPubMedCentralCrossRef
164.
Giampazolias E, Zunino B, Dhayade S, Bock F, Cloix C, Cao K, et al. Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19(9):1116–29.PubMedPubMedCentralCrossRef
165.
Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Volume 350. New York, NY: Science; 2015. pp. 328–34. 6258.
166.
Schmidt SV, Seibert S, Walch-Rückheim B, Vicinus B, Kamionka EM, Pahne-Zeppenfeld J, et al. RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation. Oncotarget. 2015;6(11):8635–47.PubMedPubMedCentralCrossRef
167.
Yang Y, Wu M, Cao D, Yang C, Jin J, Wu L, et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv. 2021;7(41):eabf6290.PubMedPubMedCentralCrossRef
168.
Zhang X, Wu J, Liu Q, Li X, Li S, Chen J, et al. mtDNA-STING pathway promotes necroptosis-dependent enterocyte injury in intestinal ischemia reperfusion. Cell Death Dis. 2020;11(12):1050.PubMedPubMedCentralCrossRef
169.
Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Therapy: J Am Soc Gene Therapy. 2011;19(3):594–601.CrossRef
170.
Yi X, Li J, Zheng X, Xu H, Liao D, Zhang T, et al. Construction of PANoptosis signature: novel target discovery for prostate cancer immunotherapy. Mol Therapy Nucleic Acids. 2023;33:376–90.CrossRef
171.
Malireddi RKS, Karki R, Sundaram B, Kancharana B, Lee S, Samir P, et al. Inflammatory cell death, PANoptosis, mediated by cytokines in Diverse Cancer lineages inhibits Tumor Growth. ImmunoHorizons. 2021;5(7):568–80.PubMedCrossRef
172.
173.
Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–36.PubMedCrossRef
174.
Shi X, Gao X, Liu W, Tang X, Liu J, Pan D, et al. Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma. Oncol Res. 2023;31(4):569–90.PubMedPubMedCentralCrossRef
175.
Wei L, Wang X, Zhou H. Interaction among inflammasome, PANoptosise, and innate immune cells in infection of influenza virus: updated review. Immun Inflamm Dis. 2023;11(9):e997.PubMedPubMedCentralCrossRef
176.
Kang S, Fernandes-Alnemri T, Rogers C, Mayes L, Wang Y, Dillon C, et al. Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3. Nat Commun. 2015;6:7515.PubMedCrossRef
177.
Babamale AO, Chen ST. Nod-like receptors: critical intracellular sensors for host protection and cell death in Microbial and parasitic infections. Int J Mol Sci. 2021;22(21).
178.
Zhou L, Lyu J, Liu F, Su Y, Feng L, Zhang X. Immunogenic PANoptosis-Initiated Cancer Sono-Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity cycle. Advanced materials (Deerfield Beach. Fla). 2024;36(2):e2305361.
179.
Qiao L, Zhu G, Jiang T, Qian Y, Sun Q, Zhao G, et al. Self-destructive copper carriers induce pyroptosis and Cuproptosis for Efficient Tumor Immunotherapy against Dormant and Recurrent Tumors. Advanced materials (Deerfield Beach. Fla). 2024;36(8):e2308241.
180.
Zhang J, Han M, Zhang J, Abdalla M, Sun P, Yang Z, et al. Syphilis mimetic nanoparticles for cuproptosis-based synergistic cancer therapy via reprogramming copper metabolism. Int J Pharm. 2023;640:123025.PubMedCrossRef
181.
Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, et al. Cuproptosis Induced by ROS responsive nanoparticles with Elesclomol and Copper Combined with αPD-L1 for enhanced Cancer Immunotherapy. Advanced materials (Deerfield Beach. Fla). 2023;35(22):e2212267.
182.
Qi F, Chang Y, Zheng R, Wu X, Wu Y, Li B, et al. Copper Phosphide Nanoparticles used for combined Photothermal and photodynamic tumor therapy. ACS Biomaterials Sci Eng. 2021;7(6):2745–54.CrossRef
183.
Deng H, Yang Y, Zuo T, Fang T, Xu Y, Yang J, et al. Multifunctional ZnO@CuS nanoparticles cluster synergize chemotherapy and photothermal therapy for tumor metastasis. Nanomedicine: Nanatechnol Biology Med. 2021;34:102399.CrossRef
184.
Liu J, Kang R, Tang D. Signaling pathways and defense mechanisms of ferroptosis. FEBS J. 2022;289(22):7038–50.PubMedCrossRef
185.
Wan X, Song L, Pan W, Zhong H, Li N, Tang B. Tumor-targeted Cascade Nanoreactor based on Metal-Organic frameworks for synergistic ferroptosis-starvation anticancer therapy. ACS Nano. 2020;14(9):11017–28.PubMedCrossRef
186.
Zheng J, Conrad M. The metabolic underpinnings of Ferroptosis. Cell Metabol. 2020;32(6):920–37.CrossRef
187.
Zuo T, Fang T, Zhang J, Yang J, Xu R, Wang Z, et al. pH-Sensitive Molecular-switch-containing polymer nanoparticle for breast Cancer Therapy with Ferritinophagy-Cascade Ferroptosis and Tumor Immune activation. Adv Healthc Mater. 2021;10(21):e2100683.PubMedCrossRef
188.
Tu H, Tang LJ, Luo XJ, Ai KL, Peng J. Insights into the novel function of system Xc- in regulated cell death. Eur Rev Med Pharmacol Sci. 2021;25(3):1650–62.PubMed
189.
Xin H, Huang Y, Tang H, Chen Y, Xia H, Zhang F, et al. Delivery of a system x(c)(-) inhibitor by a redox-responsive levodopa prodrug nanoassembly for combination ferrotherapy. J Mater Chem B. 2021;9(35):7172–81.PubMedCrossRef
190.
Zheng DW, Lei Q, Zhu JY, Fan JX, Li CX, Li C, et al. Switching apoptosis to ferroptosis: metal-Organic Network for High-Efficiency Anticancer Therapy. Nano Lett. 2017;17(1):284–91.PubMedCrossRef
191.
Shen Z, Liu T, Li Y, Lau J, Yang Z, Fan W, et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of Orthotopic Brain tumors. ACS Nano. 2018;12(11):11355–65.PubMedCrossRef
192.
Liu J, Zhan J, Zhang Y, Huang L, Yang J, Feng J, et al. Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and Cancer immunotherapy. Advanced materials (Deerfield Beach. Fla). 2024;36(9):e2309562.
193.
Song M, Xia W, Tao Z, Zhu B, Zhang W, Liu C, et al. Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. Drug Delivery. 2021;28(1):594–606.PubMedPubMedCentralCrossRef
194.
Xuan Y, Wang H, Yung MM, Chen F, Chan WS, Chan YS, et al. SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. Theranostics. 2022;12(7):3534–52.PubMedPubMedCentralCrossRef
195.
Wang J, Qin D, Tao Z, Wang B, Xie Y, Wang Y, et al. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Front Immunol. 2022;13:1056932.PubMedPubMedCentralCrossRef
196.
Hei Y, Chen Y, Li Q, Mei Z, Pan J, Zhang S, et al. Multifunctional immunoliposomes enhance the Immunotherapeutic effects of PD-L1 antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment. Small (Weinheim an Der Bergstrasse. Germany). 2022;18(9):e2105118.
197.
Hu C, Song Y, Zhang Y, He S, Liu X, Yang X, et al. Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome. Acta Pharm Sinica B. 2023;13(5):2176–87.CrossRef
198.
Zhang L, Xu Y, Cheng Z, Zhao J, Wang M, Sun Y, et al. The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis. Cancer Lett. 2024;595:217000.PubMedCrossRef
199.
Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, et al. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Differ. 2018;25(8):1457–72.PubMedPubMedCentralCrossRef
200.
He GN, Bao NR, Wang S, Xi M, Zhang TH, Chen FS. Ketamine induces ferroptosis of Liver Cancer cells by Targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Des Devel Ther. 2021;15:3965–78.PubMedPubMedCentralCrossRef
201.
202.
Bao C, Zhang J, Xian SY, Chen F. MicroRNA-670-3p suppresses ferroptosis of human glioblastoma cells through targeting ACSL4. Free Radic Res. 2021;55(7):853–64.PubMedCrossRef
203.
Zhai H, Zhong S, Wu R, Mo Z, Zheng S, Xue J, et al. Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma. Epigenetics. 2023;18(1):2192438.PubMedPubMedCentralCrossRef
204.
Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou S, et al. Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med. 2021;9(8):675.PubMedPubMedCentralCrossRef
205.
Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y, et al. TFAP2C-Mediated lncRNA PCAT1 inhibits ferroptosis in Docetaxel-resistant prostate Cancer through c-Myc/miR-25-3p/SLC7A11 signaling. Front Oncol. 2022;12:862015.PubMedPubMedCentralCrossRef
206.
Lu X, Kang N, Ling X, Pan M, Du W, Gao S. MiR-27a-3p promotes Non-small Cell Lung Cancer through SLC7A11-Mediated-ferroptosis. Front Oncol. 2021;11:759346.PubMedPubMedCentralCrossRef
207.
Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q, et al. MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021;12(1):325.PubMedPubMedCentralCrossRef
208.
Hou Y, Cai S, Yu S, Lin H. Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2021;53(3):333–41.PubMedCrossRef
209.
Zhang XY, Li SS, Gu YR, Xiao LX, Ma XY, Chen XR, et al. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis. Mol Cancer. 2024;23(1):113.PubMedPubMedCentralCrossRef
210.
Tai F, Zhai R, Ding K, Zhang Y, Yang H, Li H et al. Long non–coding RNA lung cancer–associated transcript 1 regulates ferroptosis via microRNA–34a–5p–mediated GTP cyclohydrolase 1 downregulation in lung cancer cells. Int J Oncol. 2024;64(6).
211.
Li SQ, Lv F, Xu WT, Yin YX, Wei HT, Li KZ, et al. lncRNA SNHG4 inhibits ferroptosis by orchestrating miR-150-5p/c-Myb axis in colorectal cancer. Int J Biol Macromol. 2024;268(Pt 2):131961.PubMedCrossRef
212.
Liu M, Xu C, Yang H, Jiang Q, Chen G, Wang W, et al. Pro-oncogene FBI-1 inhibits the ferroptosis of prostate carcinoma PC-3 cells via the microRNA-324-3p/GPX4 axis. J Cancer. 2024;15(13):4097–112.PubMedPubMedCentralCrossRef
213.
Zhao J, Shen J, Mao L, Yang T, Liu J, Hongbin S. Cancer associated fibroblast secreted Mir-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene. 2024;43(27):2104–14.PubMedCrossRef
214.
Cao W, He Y, Lan J, Luo S, Sun B, Xiao C, et al. FOXP3 promote the progression of glioblastoma via inhibiting ferroptosis mediated by linc00857/miR-1290/GPX4 axis. Cell Death Dis. 2024;15(4):239.PubMedPubMedCentralCrossRef
215.
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1–2):317–31.
216.
Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F, et al. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death and Differentiation. 2022;29(11):2190–202.
217.
Li K, Lin C, Li M, Xu K, He Y, Mao Y, et al. Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy. ACS nano. 2022;16(2):2381–98.
218.
Wang H, An P, Xie E, Wu Q, Fang X, Gao H, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology (Baltimore, Md). 2017;66(2):449–65.
219.
Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Müller C, Zandkarimi F, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Central Sci. 2020;6(1):41–53.
220.
Soula M, Weber RA, Zilka O, Alwaseem H, La K, Yen F, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nature Chem Bio. 2020;16(12):1351–60.
221.
Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–8.
222.
Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688–92.
223.
Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509(7498):105–9.
224.
Polishchuk EV, Concilli M, Iacobacci S, Chesi G, Pastore N, Piccolo P, et al. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Develop Cell. 2014;29(6):686–700.
225.
Sheftel AD, Stehling O, Pierik AJ, Elsässer HP, Mühlenhoff U, Webert H, et al. Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(26):11775–80.
226.
Shi Y, Ghosh M, Kovtunovych G, Crooks DR, Rouault TA. Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis. Biochi et Biophy Acta. 2012;1823(2):484–92.
227.
Xiao C, Yang L, Jin L, Lin W, Zhang F, Huang S, et al. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer. Front Gene. 2022;13:962028.
228.
Yang L, Zhang Y, Wang Y, Jiang P, Liu F, Feng N. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: a pan-cancer analysis. Front Pharm. 2022;13:938134.
229.
Huang X, Wang T, Ye J, Feng H, Zhang X, Ma X, et al. FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis. Front Gene. 2022;13:994741.
230.
Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004;10(14):4661–9.
231.
Wu G, Peng H, Tang M, Yang M, Wang J, Hu Y, et al. ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine. 2021;71:103558.
232.
Chen Z, Guo Y, Zhao D, Zou Q, Yu F, Zhang L, et al. Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers. Front Cell Dev Biol. 2021;9:808208.
233.
Cheng T, Wu Y, Liu Z, Yu Y, Sun S, Guo M, et al. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer. Front Immunol. 2022;13:970950.
234.
Li X, Ma Z, Mei L. Cuproptosis-related gene SLC31A1 is a potential predictor for diagnosis, prognosis and therapeutic response of breast cancer. American J Cancer Research. 2022;12(8):3561–80.
235.
Casteel J, Miernyk JA, Thelen JJ. Mapping the lipoylation site of Arabidopsis thaliana plastidial dihydrolipoamide S-acetyltransferase using mass spectrometry and site-directed mutagenesis. Plant Physiol Biochem. 2011;49(11):1355–61.
236.
Ni M, Solmonson A, Pan C, Yang C, Li D, Notzon A, et al. Functional assessment of lipoyltransferase-1 deficiency in cells, mice, and humans. Cell reports. 2019;27(5):1376–86.e6.
237.
Soreze Y, Boutron A, Habarou F, Barnerias C, Nonnenmacher L, Delpech H, et al. Mutations in human lipoyltransferase gene LIPT1 cause a Leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. Orphanet J rare dis. 2013;8:192.
238.
Yan C, Niu Y, Ma L, Tian L, Ma J. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. J trans med. 2022;20(1):452.
239.
Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K, et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther. 2022;7(1):54.
240.
Zhang M, Qin X, Zhao Z, Du Q, Li Q, Jiang Y, et al. A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy. Nanoscale horizons. 2022;7(2):198–210.
241.
Zhang F, Li F, Lu GH, Nie W, Zhang L, Lv Y, et al. Engineering magnetosomes for ferroptosis/immunomodulation synergism in cancer. ACS nano. 2019;13(5):5662–73.
242.
Li WP, Su CH, Chang YC, Lin YJ, Yeh CS. Ultrasound-induced reactive oxygen species mediated therapy and imaging using a fenton reaction activable polymersome. ACS nano. 2016;10(2):2017–27.
243.
Qin X, Zhang J, Wang B, Xu G, Yang X, Zou Z, et al. Ferritinophagy is involved in the zinc oxide nanoparticles-induced ferroptosis of vascular endothelial cells. Autophagy. 2021;17(12):4266–85.
244.
Zhou L, Chen J, Li R, Wei L, Xiong H, Wang C, et al. Metal-polyphenol-network coated prussian blue nanoparticles for synergistic ferroptosis and apoptosis via triggered GPX4 inhibition and concurrent in situ bleomycin toxification. Small (Weinheim an der Bergstrasse, Germany). 2021;17(47):e2103919.
245.
Fan R, Chen C, Mu M, Chuan D, Liu H, Hou H, et al. Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy. ACS nano. 2023;17(10):9126–39.
246.
Zhao X, Wang Z, Wu G, Yin L, Xu L, Wang N, et al. Apigenin-7-glucoside-loaded nanoparticle alleviates intestinal ischemia-reperfusion by ATF3/SLC7A11-mediated ferroptosis. J Control Release. 2024;366:182–93.
247.
Wang N, Zhang Q, Wang Z, Liu Y, Yang S, Zhao X, et al. A chemo/chemodynamic nanoparticle based on hyaluronic acid induces ferroptosis and apoptosis for triple-negative breast cancer therapy. Carbohydrate polymers. 2024;329:121795.
248.
Yuan H, Xia P, Sun X, Ma J, Xu X, Fu C, et al. Photothermal nanozymatic nanoparticles induce ferroptosis and apoptosis through tumor microenvironment manipulation for cancer therapy. Small (Weinheim an der Bergstrasse, Germany). 2022;18(41):e2202161.
249.
Zhang J, Zhou K, Lin J, Yao X, Ju D, Zeng X, et al. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles. Biomaterials. 2023;303:122395.
250.
Luo T, Zheng Q, Shao L, Ma T, Mao L, Wang M. Intracellular delivery of glutathione peroxidase degrader induces ferroptosis in vivo. Angewandte Chemie (International ed in English). 2022;61(39):e202206277.
251.
Ding X, Wang Z, Yu Q, Michał N, Roman S, Liu Y, et al. Superoxide Dismutase-Like Regulated Fe/Ppa@PDA/B for Synergistically Targeting Ferroptosis/Apoptosis to Enhance Anti-Tumor Efficacy. Adv Healthc Mater. 2023;12(29):e2301824.
252.
Li Y, Liu J, Chen Y, Weichselbaum RR, Lin W. Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024;11(23):e2310309.
253.
Lu Y, Pan Q, Gao W, Pu Y, He B. Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine via cuproptosis. J Mater Chem B. 2022;10(33):6296–306.
254.
Yang Z, Zhao Z, Cheng H, Shen Y, Xie A, Zhu M. In-situ fabrication of novel Au nanoclusters-Cu(2+)@sodium alginate/hyaluronic acid nanohybrid gels for cuproptosis enhanced photothermal/photodynamic/chemodynamic therapy via tumor microenvironment regulation. J Colloid Interface Sci. 2023;641:215–28.
255.
Lu X, Chen X, Lin C, Yi Y, Zhao S, Zhu B, et al. Elesclomol loaded copper oxide nanoplatform triggers cuproptosis to enhance antitumor immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024;11(18):e2309984.
256.
Zhao F, Yu H, Liang L, Wang C, Shi D, Zhang X, et al. Redox homeostasis disruptors based on metal-phenolic network nanoparticles for chemo/chemodynamic synergistic tumor therapy through activating apoptosis and cuproptosis. Adv Healthc Mater. 2023;12(29):e2301346.
257.
Zhou J, Yu Q, Song J, Li S, Li XL, Kang BK, et al. Photothermally triggered copper payload release for cuproptosis-promoted cancer synergistic therapy. Angewandte Chemie (International ed in English). 2023;62(12):e202213922.
Metadata
Title
Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope
Authors
Xiaojie Zhang
Bufu Tang
Jinhua Luo
Yang Yang
Qiaoyou Weng
Shiji Fang
Zhongwei Zhao
Jianfei Tu
Minjiang Chen
Jiansong Ji
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-024-02130-8

Other articles of this Issue 1/2024

Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance

Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication

NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer

Writers, readers, and erasers RNA modifications and drug resistance in cancer

SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization

Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits